Acumen Pharmaceuticals, Inc. (ABOS)
- Previous Close
3.1900 - Open
3.1900 - Bid 3.1500 x 100
- Ask 3.1900 x 300
- Day's Range
3.1350 - 3.2100 - 52 Week Range
1.8100 - 11.3100 - Volume
140,590 - Avg. Volume
335,179 - Market Cap (intraday)
190.453M - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0800 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.80
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
acumenpharm.comRecent News: ABOS
Performance Overview: ABOS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABOS
Valuation Measures
Market Cap
190.45M
Enterprise Value
-24.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.71
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.08%
Return on Equity (ttm)
-22.98%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-52.37M
Diluted EPS (ttm)
-1.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
243.52M
Total Debt/Equity (mrq)
11.63%
Levered Free Cash Flow (ttm)
-28.24M